{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:46:35Z","timestamp":1790045195951,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Gene Therapies, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40120-023-00489-2","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T10:02:36Z","timestamp":1684922556000},"page":"1205-1220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England"],"prefix":"10.1007","volume":"12","author":[{"given":"Diana","family":"Weidlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Kausar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Howells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"issue":"4","key":"489_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004.","journal-title":"Neurol Clin"},{"issue":"8","key":"489_CR2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68(8):979\u201384.","journal-title":"Arch Neurol"},{"issue":"1","key":"489_CR3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"489_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(1):71.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"489_CR5","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1542\/peds.2004-0668","volume":"114","author":"BH Chung","year":"2004","unstructured":"Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004;114(5):e548\u201353.","journal-title":"Pediatrics"},{"key":"489_CR6","unstructured":"Spierziekten Nederland. Richtlijn spinale musculaire atrofie (SMA) type 1. 2018. https:\/\/www.spierziekten.nl\/fileadmin\/user_upload\/VSN\/documenten\/Hulpverlenersinformatie\/Richtlijnen\/R037-SMA1-Richtlijn-2018.pdf. Accessed Jan 18, 2023."},{"issue":"1","key":"489_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27\u201332.","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"489_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.10425","volume":"110","author":"S Ogino","year":"2002","unstructured":"Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110(4):301\u20137.","journal-title":"Am J Med Genet"},{"key":"489_CR9","unstructured":"van der Pol L. Cost-effectiveness of newborn screening for spinal muscular atrophy [expert opinion meeting]. 28 Sept 2020. Cisco Webex video conference."},{"key":"489_CR10","unstructured":"Spinal Muscular Atrophy UK. What is 5q spinal muscular atrophy? 2023. https:\/\/smauk.org.uk\/what-is-5q-sma. Accessed Jan 18, 2023."},{"issue":"3","key":"489_CR11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","volume":"21","author":"S Ramdas","year":"2020","unstructured":"Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020;21(3):307\u201315.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"489_CR12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352.","journal-title":"Lancet Neurol"},{"issue":"5","key":"489_CR13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427\u201335.","journal-title":"N Engl J Med"},{"issue":"7","key":"489_CR14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"489_CR15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"489_CR16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic break as infantile- onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"18","key":"489_CR17","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"10","key":"489_CR18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832\u201341.","journal-title":"Lancet Neurol"},{"issue":"7","key":"489_CR19","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1390\u20137.","journal-title":"Nat Med"},{"issue":"7","key":"489_CR20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381\u20139.","journal-title":"Nat Med"},{"issue":"2","key":"489_CR21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"489_CR22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2017.02.014","volume":"27","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Sejersen T, Mercuri E, on behalf of the ENMC SMA Workshop Study Group. 218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA. Naarden, The Netherlands, 19\u201321 February 2016. Neuromuscul Disord. 2017;27(6):596\u2013605.","journal-title":"Neuromuscul Disord"},{"key":"489_CR23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","volume":"15","author":"T Dangouloff","year":"2019","unstructured":"Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag. 2019;15:1153\u201361.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"489_CR24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JND-190428","volume":"6","author":"K Vill","year":"2019","unstructured":"Vill K, K\u00f6lbel H, Schwartz O, Blaschek A, Olgem\u00f6ller B, Harms E, et al. One year of newborn screening for SMA\u2014results of a German pilot project. J Neuromuscul Dis. 2019;6(4):503\u201315.","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"489_CR25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","volume":"92","author":"STF Shih","year":"2021","unstructured":"Shih STF, Farrar MA, Wiley V, Chambers G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry. 2021;92(12):1296\u2013304.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"489_CR26","doi-asserted-by":"crossref","first-page":"19922","DOI":"10.1038\/s41598-021-99496-2","volume":"11","author":"F Boemer","year":"2021","unstructured":"Boemer F, Caberg J-H, Beckers P, Dideberg V, di Fiore S, Bours V, et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci Rep. 2021;11(1):19922.","journal-title":"Sci Rep"},{"issue":"5","key":"489_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dmcn.15117","volume":"64","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva AM, Kariyawasam DST, Best S, Wiley V, Farrar MA. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. Dev Med Child Neurol. 2022;64(5):625\u201332. https:\/\/doi.org\/10.1111\/dmcn.15117.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"489_CR28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/dmcn.15286","volume":"65","author":"T Dangouloff","year":"2023","unstructured":"Dangouloff T, Hiligsmann M, Deconinck N, D\u2019Amico A, Seferian AM, Boemer F, et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Dev Med Child Neurol. 2023;65(1):67\u201377.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"489_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","volume":"30","author":"T Dangouloff","year":"2020","unstructured":"Dangouloff T, Burghes A, Tizzano EF, Servais L. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10\u201312, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord. 2020;30(1):93\u2013103. https:\/\/doi.org\/10.1016\/j.nmd.2019.11.002.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"489_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","volume":"31","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Vr\u0161\u010daj E, Servais L, Osredkar D. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord. 2021;31(6):574\u201382. https:\/\/doi.org\/10.1016\/j.nmd.2021.03.007.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"489_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ijns8030045","volume":"8","author":"STF Shih","year":"2022","unstructured":"Shih STF, Keller E, Wiley V, Farrar MA, Wong M, Chambers GM. Modelling the cost-effectiveness and budget impact of a newborn screening program for spinal muscular atrophy and severe combined immunodeficiency. Int J Neonatal Screen. 2022;8(3):45. https:\/\/doi.org\/10.3390\/ijns8030045.","journal-title":"Int J Neonatal Screen"},{"key":"489_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","volume":"227","author":"A Jalali","year":"2020","unstructured":"Jalali A, Rothwell E, Botkin JR, Anderson RA, Butterfield RJ, Nelson RE. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy. J Pediatr. 2020;227:274-80.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2020.07.033.","journal-title":"J Pediatr"},{"issue":"10","key":"489_CR33","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","volume":"25","author":"R Velikanova","year":"2022","unstructured":"Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Cost-effectiveness of newborn screening for spinal muscular atrophy in The Netherlands. Value Health. 2022;25(10):1696\u2013704.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"489_CR34","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.nmd.2022.07.080","volume":"32","author":"T Dangouloff","year":"2022","unstructured":"Dangouloff T, Thokala P, Daron A, Delstanche S, Servais L, Hiligsmann MP. 44 Cost-effectiveness of spinal muscular atrophy newborn screening in Belgium. Neuromuscul Disord. 2022;32(Suppl 1):S60.","journal-title":"Neuromuscul Disord"},{"key":"489_CR35","unstructured":"Office for National Statistics. Live births. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/livebirths. Accessed Jan 18, 2023."},{"issue":"3","key":"489_CR36","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol. 2018;25(3):512\u20138.","journal-title":"Eur J Neurol"},{"key":"489_CR37","unstructured":"National Institute for Health and Care Excellence (NICE). NICE final draft guidance approves life-changing gene therapy for treating spinal muscular atrophy. 8 Mar 2021. https:\/\/www.nice.org.uk\/news\/article\/nice-approves-life-changing-gene-therapy-for-treating-spinal-muscular-atrophy. Accessed Jan 13, 2023."},{"issue":"1","key":"489_CR38","doi-asserted-by":"crossref","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7(1):1601484.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"489_CR39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","volume":"125","author":"L Alias","year":"2009","unstructured":"Alias L, Bernal S, Fuentes-Prior P, Barcel\u00f3 MJ, Also E, Mart\u00ednez-Hern\u00e1ndez R, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet. 2009;125(1):29\u201339.","journal-title":"Hum Genet"},{"key":"489_CR40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","volume":"190","author":"YH Chien","year":"2017","unstructured":"Chien YH, Chiang SC, Weng WC, Lee NC, Lin CJ, Hsieh WS, et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr. 2017;190:124-9.e1.","journal-title":"J Pediatr"},{"issue":"3","key":"489_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/ijns7030033","volume":"7","author":"K Hale","year":"2021","unstructured":"Hale K, Ojodu J, Singh S. Landscape of spinal muscular atrophy newborn screening in the United States: 2018\u20132021. Int J Neonatal Screen. 2021;7(3):33. https:\/\/doi.org\/10.3390\/ijns7030033.","journal-title":"Int J Neonatal Screen"},{"issue":"3","key":"489_CR42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","volume":"22","author":"DST Kariyawasam","year":"2020","unstructured":"Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med. 2020;22(3):557\u201365.","journal-title":"Genet Med"},{"issue":"8","key":"489_CR43","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","volume":"22","author":"DM Kay","year":"2020","unstructured":"Kay DM, Stevens CF, Parker A, Saavedra-Matiz CA, Sack V, Chung WK, et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet Med. 2020;22(8):1296\u2013302.","journal-title":"Genet Med"},{"issue":"1","key":"489_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","volume":"16","author":"K Vill","year":"2021","unstructured":"Vill K, Schwartz O, Blaschek A, Gl\u00e4ser D, Nennstiel U, Wirth B, et al. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis. 2021;16(1):153. https:\/\/doi.org\/10.1186\/s13023-021-01783-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"489_CR45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.ejhg.5201288","volume":"12","author":"S Ogino","year":"2004","unstructured":"Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12(12):1015\u201323.","journal-title":"Eur J Hum Genet"},{"key":"489_CR46","unstructured":"M\u00fcller-Felber W. SMA NBS programme learnings from Germany. Presented at: Biogen-Organized Satellite Symposium at the 14th Congress of the European Paediatric Neurology Society (EPNS). 2022. https:\/\/assets.ctfassets.net\/evoe4hvfuo1p\/3m8uF02OW6vzFWJo6ZeKJV\/7f27fee50f2d7a87109cedb48f8a6d11\/P_SMA_Mueller-Felber_Slides_EPNS_2022_UK_ENG_4___-__Read-Only.pdf. Accessed Jan 18, 2023."},{"issue":"5","key":"489_CR47","doi-asserted-by":"crossref","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Rava L, Bignamini E, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509\u201314.","journal-title":"Pediatrics"},{"issue":"6","key":"489_CR48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391.","journal-title":"Ann Neurol"},{"issue":"1","key":"489_CR49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1):67\u201372.","journal-title":"J Neurol Sci"},{"key":"489_CR50","unstructured":"Office for National Statistics. National life tables, UK: 2014 to 2016. 27 Sept 2017. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2014to2016. Accessed Jan 18, 2023."},{"key":"489_CR51","unstructured":"Heijnen ML, Jansen M, van Gorp A, Hillen D, Elsinghorst E, Klein A. Uitvoeringstoets toevoeging Spinale Musculaire Atrophie aan de neonatale hielprikscreening. 2020. https:\/\/www.rivm.nl\/bibliotheek\/rapporten\/2020-0105.pdf. Accessed Jan 18, 2023."},{"key":"489_CR52","unstructured":"Oxford University Hospitals NHS Foundation Trust. Oxford Genetics Laboratories Price List For Rare Disease Services from April 2022. 2022. https:\/\/www.ouh.nhs.uk\/services\/referrals\/genetics\/genetics-laboratories\/rare-disease-genomics\/documents\/price-list.pdf. Accessed Jan 18, 2023."},{"key":"489_CR53","unstructured":"NHS 75 England. National Cost Collection for the NHS 2019\/2020. 2020. https:\/\/www.england.nhs.uk\/national-cost-collection\/. Accessed Jan 18, 2023."},{"key":"489_CR54","unstructured":"Personal Social Services Research Unit. Unit Costs of Health and Social Care 2021. 2022. https:\/\/kar.kent.ac.uk\/92342\/. Accessed Jan 18, 2023."},{"issue":"15","key":"489_CR55","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","volume":"94","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, van Eijk RPA, Cuppen I, Veldhoen ES, et al. Population-based analysis of survival in spinal muscular atrophy. Neurology. 2020;94(15):e1634\u201344.","journal-title":"Neurology"},{"issue":"9","key":"489_CR56","first-page":"PA725-6","volume":"20","author":"R Thompson","year":"2017","unstructured":"Thompson R, Vaidya S, Teynor M. The utility of different approachs to developing health utilities data in childhood rare diseases: a case study in spinal muscular atrophy (SMA). Value Health. 2017;20(9):PA725-6.","journal-title":"Value Health"},{"key":"489_CR57","unstructured":"Tappenden P, Hamilton J, Kaltenthaler E, Hock E, Rawdin A, Mukuria C, et al. Nusinersen for treating spinal muscular atrophy: a single technology appraisal. 28 May 2018. https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2021139. Accessed Jan 18, 2023."},{"issue":"5","key":"489_CR58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318.","journal-title":"Value Health"},{"key":"489_CR59","unstructured":"NICE. NICE Health Technology Evaluations: the Manual. 31 Jan 2022. https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741. Accessed Jan 18, 2023."},{"issue":"1","key":"489_CR60","doi-asserted-by":"crossref","first-page":"1889841","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9(1):1889841.","journal-title":"J Mark Access Health Policy"},{"issue":"12","key":"489_CR61","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1007\/s00415-022-11319-0","volume":"269","author":"T Wang","year":"2022","unstructured":"Wang T, Scuffham P, Byrnes J, Downes M. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia. J Neurol. 2022;269(12):6544\u201354.","journal-title":"J Neurol"},{"key":"489_CR62","unstructured":"Roche. SMA Screening for Newborns in Europe. 2022. https:\/\/www.roche.com\/stories\/sma-screening-for-newborns-in-europe. Accessed Jan 18, 2023."},{"issue":"3","key":"489_CR63","volume":"15","author":"MC Pera","year":"2020","unstructured":"Pera MC, Coratti G, Berti B, D\u2019Amico A, Sframeli M, Albamonte E, et al. Diagnostic journey in spinal muscular atrophy: is it still an odyssey? PLoS\u00a0One. 2020;15(3): e0230677.","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"489_CR64","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3233\/JND-221510","volume":"9","author":"A Blaschek","year":"2022","unstructured":"Blaschek A, K\u00f6lbel H, Schwartz O, K\u00f6hler C, Gl\u00e4ser D, Eggermann K, et al. Newborn screening for SMA: can a wait-and-see strategy be responsibly justified in patients with four SMN2 copies? J Neuromuscul Dis. 2022;9(5):597\u2013605.","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"489_CR65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.0000000000007836","volume":"93","author":"DC Schorling","year":"2019","unstructured":"Schorling DC, Becker J, Pechmann A, Langer T, Wirth B, Kirschner J. Discrepancy in redetermination of SMN2 copy numbers in children with SMA. Neurology. 2019;93(6):267\u20139.","journal-title":"Neurology"},{"issue":"3","key":"489_CR66","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1212\/WNL.0000000000009907","volume":"95","author":"T Dangolouff","year":"2020","unstructured":"Dangolouff T, Boemer F, Dideberg V, Caberg J-H, Servais L. Reader response: discrepancy in redetermination of SMN2 copy numbers in children with SMA. Neurology. 2020;95(3):144\u20135.","journal-title":"Neurology"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00489-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T17:34:01Z","timestamp":1702488841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00489-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00489-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.02.09.23285715","asserted-by":"object"}]},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"25 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}